Form S-3

Wabtec Announces Pricing of Senior Notes Offering

Retrieved on: 
Monday, February 26, 2024
Trucking, Rail, Maritime, Logistics, Supply Chain Management, Transport, Manufacturing, Machinery, J.P. Morgan & Co., Prospectus, TD Securities, EDGAR, Sale, Debt-to-GDP ratio, Form, Security (finance), Hand, Corporation, Form S-3, Credit

Wabtec Corporation (NYSE: WAB) (“Wabtec”) today announced that it has priced a public offering of $500 million aggregate principal amount of 5.611% Senior Notes due 2034 (the “Notes”).

Key Points: 
  • Wabtec Corporation (NYSE: WAB) (“Wabtec”) today announced that it has priced a public offering of $500 million aggregate principal amount of 5.611% Senior Notes due 2034 (the “Notes”).
  • The Notes will be guaranteed by each of Wabtec’s current and future subsidiaries that guarantee its indebtedness under its credit agreements or any other debt of Wabtec or any other guarantor.
  • Wabtec intends to use the net proceeds from the offering, together with cash on hand and/or borrowings under a new credit agreement expected to be entered into by Wabtec concurrently with the closing of the sale of the Notes (the “2024 Credit Agreement”), to repay all of its outstanding 4.15% Senior Notes due 2024 at maturity (the “2024 Notes”), which is scheduled to occur on March 15, 2024.
  • Before you invest, you should read the registration statement, including the prospectus, and prospectus supplement, and other documents Wabtec has filed with the SEC for more complete information about Wabtec and this offering.

Clearwater Analytics Announces Launch of Secondary Offering of Class A Common Stock

Retrieved on: 
Wednesday, March 6, 2024
Attention, Prospectus, Accounting, Telephone, Common stock, Sale, Common, Form, Broadridge Financial Solutions, Software as a service, Form S-3, Security (finance)

BOISE, Idaho, March 6, 2024 /PRNewswire/ -- Clearwater Analytics Holdings, Inc. ("Clearwater" or the "Company") (NYSE: CWAN), a leading provider of SaaS-based investment management, accounting, reporting, and analytics solutions, today announced that it has launched an underwritten secondary public offering of an aggregate of 16,250,000 shares of the Company's Class A common stock, par value $0.001 per share (the "Common Stock").

Key Points: 
  • BOISE, Idaho, March 6, 2024 /PRNewswire/ -- Clearwater Analytics Holdings, Inc. ("Clearwater" or the "Company") (NYSE: CWAN), a leading provider of SaaS-based investment management, accounting, reporting, and analytics solutions, today announced that it has launched an underwritten secondary public offering of an aggregate of 16,250,000 shares of the Company's Class A common stock, par value $0.001 per share (the "Common Stock").
  • The Company is conducting a resale of Common Stock on behalf of certain affiliates of Welsh, Carson, Anderson & Stowe (collectively, the "Selling Stockholders").
  • The Company will not receive any proceeds from the sale of the Common Stock by the Selling Stockholders.
  • The Common Stock is listed on the New York Stock Exchange under the ticker symbol "CWAN."

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration

Retrieved on: 
Monday, February 26, 2024
Security (finance), Form S-3

CRANFORD, N.J., Feb. 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the Company filed a Form S-3 shelf registration on February 23, 2024 with the Securities and Exchange Commission to replace its currently effective shelf registration statement that expires in April 2024 pursuant to SEC rules.

Key Points: 
  • CRANFORD, N.J., Feb. 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the Company filed a Form S-3 shelf registration on February 23, 2024 with the Securities and Exchange Commission to replace its currently effective shelf registration statement that expires in April 2024 pursuant to SEC rules.

Bakkt Shelf Registration Statement Declared Effective by the SEC

Retrieved on: 
Wednesday, February 14, 2024
Professional Services, Blockchain, Technology, Cryptocurrency, Finance, Fintech, Digital Cash Management, Digital Assets, Bakkt, Security (finance), Prospectus, Sale, Form S-3, Form

Bakkt Holdings, Inc. (“Bakkt”) (NYSE: BKKT) announced that its “universal shelf” registration statement on Form S-3 was declared effective by the Securities and Exchange Commission (the "SEC") on February 14, 2024.

Key Points: 
  • Bakkt Holdings, Inc. (“Bakkt”) (NYSE: BKKT) announced that its “universal shelf” registration statement on Form S-3 was declared effective by the Securities and Exchange Commission (the "SEC") on February 14, 2024.
  • This registration statement allows Bakkt, so long as it is effective, to raise up to an aggregate of $150 million of capital in one or more offerings over the subsequent three years.
  • If Bakkt decides to raise capital in a future offering using such registration statement, Bakkt will describe the specific details of that future offering in a prospectus supplement that is filed with the SEC.
  • Bakkt believes the flexibility of a shelf registration on Form S-3 will provide the Company with significant benefits when raising capital in the future.

Atlanticus Closes Option in connection with Offering of Senior Notes

Retrieved on: 
Wednesday, February 14, 2024
Prospectus, Suite, Note, Sale, Debt-to-GDP ratio, Form, Atlanticus, Telephone, LLP, Security (finance), Form S-3, Offering, Duane Morris

ATLANTA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” “the Company”, “we,” “our” or “us”), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced the closing of the underwriters’ option in connection with its underwritten registered public offering (the “Offering”) of 9.25% Senior Notes due 2029 (the “Notes”).

Key Points: 
  • ATLANTA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” “the Company”, “we,” “our” or “us”), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced the closing of the underwriters’ option in connection with its underwritten registered public offering (the “Offering”) of 9.25% Senior Notes due 2029 (the “Notes”).
  • Atlanticus issued an additional 290,000 Notes and received additional net proceeds of approximately $7.0 million after deducting underwriting discounts and commissions, but before deducting expenses and the structuring fee.
  • B. Riley Securities, Inc., Janney Montgomery Scott LLC, Ladenburg Thalmann & Co. Inc., William Blair & Co., L.L.C., and BTIG, LLC acted as book-running managers for the Offering.
  • Brownstone Investment Group, LLC acted as co-manager for the Offering.

PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock

Retrieved on: 
Wednesday, February 7, 2024
Janus, Security (finance), SVB Securities, Research, Form S-3, Telephone, Prospectus, Sale, State Street, Form, Pharmaceutical industry

The aggregate gross proceeds to PepGen from this offering are expected to be approximately $80.1 million, before deducting underwriting discounts and commissions and offering expenses payable by PepGen.

Key Points: 
  • The aggregate gross proceeds to PepGen from this offering are expected to be approximately $80.1 million, before deducting underwriting discounts and commissions and offering expenses payable by PepGen.
  • The offering is expected to close on or about February 9, 2024, subject to customary closing conditions.
  • Leerink Partners is acting as the sole book-running manager for the offering.
  • PepGen currently intends to use the net proceeds from this offering to fund ongoing research and clinical development of its product candidates, as well as for working capital and other general corporate purposes.

BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market

Retrieved on: 
Tuesday, February 6, 2024
Roth Capital Partners, Security (finance), Form S-3, Exercise, Sale, Form

The aggregate gross proceeds from the exercise of the existing warrants and the payment of the new warrants, as described below, is expected to total approximately $8.1 million, before deducting financial advisory fees.

Key Points: 
  • The aggregate gross proceeds from the exercise of the existing warrants and the payment of the new warrants, as described below, is expected to total approximately $8.1 million, before deducting financial advisory fees.
  • The reduction of the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules.
  • The shares of common stock issuable upon exercise of the warrants are registered for issuance pursuant to a registration statement on Form S-1, as amended (File No.
  • The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable under state securities laws.

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Retrieved on: 
Thursday, February 1, 2024
Security (finance), Form S-3, Telephone, Exercise, Equity capital markets, Patient, Attention, Prospectus, Lexington Avenue, Broadridge Financial Solutions, Therapy, Evercore, Sale, Form

The gross proceeds to Vera from the offering, before deducting underwriting discounts and commissions and offering expenses, are approximately $287.5 million.

Key Points: 
  • The gross proceeds to Vera from the offering, before deducting underwriting discounts and commissions and offering expenses, are approximately $287.5 million.
  • J.P. Morgan, TD Cowen and Evercore ISI acted as joint book-running managers for the offering.
  • A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available for free on the SEC’s website located at http://www.sec.gov.
  • A final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available for free on the SEC’s website located at http://www.sec.gov.

Atlanticus Closes $50 Million Offering of Senior Notes

Retrieved on: 
Tuesday, January 30, 2024
Duane Morris, Security (finance), Offering, Form S-3, Note, Prospectus, Debt-to-GDP ratio, Sale, Suite, Telephone, LLP, Form

ATLANTA, Jan. 30, 2024 (GLOBE NEWSWIRE) --  Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” “the Company”, “we,” “our” or “us”), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced the closing of its previously announced underwritten registered public offering (the “Offering”) of $50 million aggregate principal amount of 9.25% Senior Notes due 2029 (the “Notes”).

Key Points: 
  • ATLANTA, Jan. 30, 2024 (GLOBE NEWSWIRE) --  Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” “the Company”, “we,” “our” or “us”), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced the closing of its previously announced underwritten registered public offering (the “Offering”) of $50 million aggregate principal amount of 9.25% Senior Notes due 2029 (the “Notes”).
  • The Offering resulted in net proceeds of approximately $48.3 million after deducting underwriting discounts and commissions, but before deducting expenses and the structuring fee.
  • The Company granted the underwriters a 30-day option to purchase up to an additional $7.5 million aggregate principal amount of the Notes in connection with the Offering.
  • B. Riley Securities, Inc., Janney Montgomery Scott LLC, Ladenburg Thalmann & Co. Inc., William Blair & Co., L.L.C., and BTIG, LLC acted as book-running managers for the Offering.

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Retrieved on: 
Tuesday, January 30, 2024
Security (finance), Form S-3, Telephone, Equity capital markets, Patient, Attention, Prospectus, Lexington Avenue, Broadridge Financial Solutions, Therapy, Evercore, Sale, Form

BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an upsized underwritten public offering of 8,064,517 shares of its Class A common stock at a price to the public of $31.00 per share.

Key Points: 
  • BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an upsized underwritten public offering of 8,064,517 shares of its Class A common stock at a price to the public of $31.00 per share.
  • The gross proceeds to Vera from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $250.0 million.
  • In addition, Vera has granted the underwriters a 30-day option to purchase up to an additional 1,209,677 shares of Class A common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on February 1, 2024, subject to the satisfaction of customary closing conditions.